CytoMed Expands Research Collaboration Into China After Entering Into MOU With China-Based Hangzhou CNK Therapeutics Co., Ltd.
Portfolio Pulse from Happy Mohamed
Singapore-based biopharmaceutical company CytoMed Therapeutics Limited (NASDAQ:GDTC) has entered into a Memorandum of Understanding (MOU) with China-based Hangzhou CNK Therapeutics Co., Ltd. The MOU allows CytoMed to use CNK's PiggyBac technology to enhance its cell-based immunotherapies for cancer treatment. The agreement has an initial duration of one year, with a possibility of renewal and potential for a joint venture to conduct clinical trials in China.
August 29, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytoMed's partnership with CNK could enhance its cancer treatment technology and potentially open up opportunities for clinical trials in China. This could have a positive impact on the company's growth and stock value.
The partnership with CNK allows CytoMed to use a technology that could enhance the efficacy of its cancer treatments. This could lead to improved product offerings and potentially increase the company's market share. Additionally, the potential for a joint venture to conduct clinical trials in China could open up a new market for CytoMed, potentially leading to increased revenues and a positive impact on its stock value.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100